Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells

Navinci partners with Oncolab GmbH, Austria, to supply reagents to their P53 Prions – A novel biomarker test for circulating tumor cells This innovative test from OncoLab (Austria) identifies cancer cells via p53 prions and is based on the proprietary proximity ligation technology from Navinci. The test kits can be used with tissues, cells, and…

Navinci Diagnostics AB and Lucerna-Chem AG have entered a distribution agreement for the Swiss market.

Uppsala and Luzern, September 2021. Navinci Diagnostics AB and Lucerna-Chem AG have entered a distribution agreement for the Swiss market.   ”Switzerland is an important market for Navinci and Lucerna-Chem is an excellent organization for us to partner with as they have a strong presence in the region, customer base, and network. We much look…